UY37534A - Metodo para el tratamiento de enfermedades fibroticas utilizando el interferon-lambda - Google Patents

Metodo para el tratamiento de enfermedades fibroticas utilizando el interferon-lambda

Info

Publication number
UY37534A
UY37534A UY0001037534A UY37534A UY37534A UY 37534 A UY37534 A UY 37534A UY 0001037534 A UY0001037534 A UY 0001037534A UY 37534 A UY37534 A UY 37534A UY 37534 A UY37534 A UY 37534A
Authority
UY
Uruguay
Prior art keywords
treatment
interferon
lambda
fibrotic diseases
fibrosis
Prior art date
Application number
UY0001037534A
Other languages
English (en)
Inventor
Scott Johnson Thimothy
Breda Twomey
Janine Powers
Original Assignee
Ucb Biopharma Sprl Y Five Prime Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Biopharma Sprl Y Five Prime Therapeutics Inc filed Critical Ucb Biopharma Sprl Y Five Prime Therapeutics Inc
Publication of UY37534A publication Critical patent/UY37534A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a métodos para el tratamiento de la fibrosis. La invención describe una nueva investigación que demuestra que el interferón lambda tiene efectos antifibróticos que actúan directamente tanto in vitro como in vivo y puede usarse para proporcionar nuevas terapias eficaces para el tratamiento de múltiples tipos de la fibrosis
UY0001037534A 2016-12-20 2017-12-20 Metodo para el tratamiento de enfermedades fibroticas utilizando el interferon-lambda UY37534A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1621728.3A GB201621728D0 (en) 2016-12-20 2016-12-20 Methods

Publications (1)

Publication Number Publication Date
UY37534A true UY37534A (es) 2018-09-28

Family

ID=58284677

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037534A UY37534A (es) 2016-12-20 2017-12-20 Metodo para el tratamiento de enfermedades fibroticas utilizando el interferon-lambda

Country Status (12)

Country Link
US (2) US20190374610A1 (es)
EP (1) EP3558342A1 (es)
JP (2) JP2020511415A (es)
CN (1) CN110381985A (es)
AR (1) AR110404A1 (es)
BR (1) BR112019012084A2 (es)
CA (1) CA3044949A1 (es)
EA (1) EA201991175A1 (es)
GB (1) GB201621728D0 (es)
TW (1) TW201828973A (es)
UY (1) UY37534A (es)
WO (1) WO2018115199A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020041636A1 (en) * 2018-08-23 2020-02-27 Exalt Therapeutics, Llc Modified ifnl3 polypeptides comprising a pharmacokinetic enhancing moiety and their uses
JP2022540699A (ja) 2019-07-18 2022-09-16 ウエヌイグレックオ・ファーマ インターフェロンの有害作用を減少させる方法
CN110882381B (zh) * 2019-12-18 2020-11-17 中国人民解放军陆军军医大学第一附属医院 重组IFN-λ1蛋白在制备防治炎症性骨丢失药物中的应用
WO2021119749A1 (en) * 2019-12-20 2021-06-24 The Council Of The Queensland Institute Of Medical Research Treatment of gastrointestinal disease
CN114736878B (zh) * 2021-01-07 2024-04-19 秦皇岛摩登狗生物科技有限公司 共表达猪干扰素l3和猪白介素22重组杆状病毒及应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9113120D0 (en) 1991-06-18 1991-08-07 Kodak Ltd Photographic processing apparatus
HUP0303645A3 (en) 2001-04-06 2005-12-28 Maxygen Holdings Ltd Georgetow Interferon gamma polypeptide variants
EP1551369A4 (en) 2002-08-28 2007-05-09 Intermune Inc COMBINATION THERAPY FOR THE TREATMENT OF FIBROTIC DISEASES
WO2004078207A1 (en) 2003-02-28 2004-09-16 Intermune, Inc. Interferon drug therapy for the treatment of viral diseases and liver fibrosis
WO2004078194A1 (en) 2003-02-28 2004-09-16 Intermune, Inc. Interferon drug therapy for the treatment of viral diseases and liver fibrosis
WO2004105684A2 (en) 2003-05-16 2004-12-09 Intermune, Inc. Combination therapy for proliferative disorders
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
ES2551439T5 (es) 2003-07-01 2018-11-08 Ucb Biopharma Sprl Fragmentos Fab de anticuerpos modificados
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
WO2005067454A2 (en) * 2003-12-23 2005-07-28 Valeant Pharmaceuticals North America Combination therapy for treating hepatitis c virus infection
WO2005110478A2 (en) 2004-04-13 2005-11-24 Intermune, Inc. Combination therapy for treating fibrotic disorders
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
JP2009529027A (ja) 2006-03-08 2009-08-13 ビオメトード ヒトインターフェロンガンマ（ＩＦＮγ）変異体
ES2667729T3 (es) 2007-09-26 2018-05-14 Ucb Biopharma Sprl Fusiones de anticuerpos con doble especificidad
CA2727026A1 (en) * 2008-06-05 2009-12-10 Zymogenetics, Llc Use of pegylated type iii interferons for the treatment of hepatitis c
EP2344546A1 (en) 2008-10-13 2011-07-20 Zymogenetics, Inc. Single chain fc type iii interferons and methods of using same
WO2010048468A1 (en) 2008-10-23 2010-04-29 Concert Pharmaceuticals, Inc. Deuterated macrocyclic inhibitors of viral ns3 protease
EP2350124A1 (en) * 2008-11-20 2011-08-03 Zymogenetics, Inc. Il-29 mutants and uses thereof
WO2011075605A2 (en) * 2009-12-18 2011-06-23 Alios Biopharma, Inc. Hyperglycosylated interferon variants and methods of use
IT1400236B1 (it) 2010-05-10 2013-05-24 Univ Bari Impiego di composti noti per il trattamento dell'insufficienza renale cronica(irc)
CN102584979B (zh) * 2011-01-18 2015-10-14 北京凯因科技股份有限公司 PEG化干扰素λ
CA2869899C (en) 2012-03-28 2021-06-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A novel interferon-.lambda.4 (ifnl4) protein, related nucleic acid molecules, and uses thereof
JP2019505553A (ja) * 2016-02-19 2019-02-28 アイガー・バイオファーマシューティカルズ・インコーポレイテッドＥｉｇｅｒ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． インターフェロンラムダによるデルタ型肝炎ウイルス感染の処置

Also Published As

Publication number Publication date
BR112019012084A2 (pt) 2019-11-12
EP3558342A1 (en) 2019-10-30
TW201828973A (zh) 2018-08-16
WO2018115199A1 (en) 2018-06-28
JP2022081677A (ja) 2022-05-31
EA201991175A1 (ru) 2019-11-29
CN110381985A (zh) 2019-10-25
US20190374610A1 (en) 2019-12-12
US20240000893A1 (en) 2024-01-04
GB201621728D0 (en) 2017-02-01
US11975046B2 (en) 2024-05-07
CA3044949A1 (en) 2018-06-28
JP2020511415A (ja) 2020-04-16
AR110404A1 (es) 2019-03-27

Similar Documents

Publication Publication Date Title
UY37534A (es) Metodo para el tratamiento de enfermedades fibroticas utilizando el interferon-lambda
IL290809B1 (en) Tau-protein targeted protacs and related methods of use
EA201790398A1 (ru) Способы лечения заболевания печени
GT201700081A (es) Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
GT201600185A (es) Moléculas de anticuerpo que se unen a lag-3 y usos de las mismas
NI201600071A (es) Compuestos de inhibidor de autotaxina
EA201691582A1 (ru) Новые фармацевтические препараты
CL2015002807A1 (es) Terapia de combinación
UY34675A (es) ?proceso y aparato para tratar superficies de metal?.
MX2015009058A (es) Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias.
UY36920A (es) Formulaciones de aminoácidos de liberación modificada administradas por vía oral
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
CR20150637A (es) Tratamiento de enfermedades miopaticas y neurodegenerativas por agregación de proteina mediante administración parenteral
MX2019005779A (es) Metodos para tratar trastornos del desarrollo y/o trastornos convulsivos con flupirtina.
CR20150585A (es) Anticuerpos anti-igf-1r con abolición de la unión al fcrn y su utilización en el tratamiento de enfermedades oculares vasculares
SG10201405683YA (en) Emission Source And Method Of Forming The Same
CL2015002181A1 (es) Tratamiento de formas progresivas de esclerosis múltiple con laquinimod.
IL248080A0 (en) System and method for identifying sources associated with biological arrhythmias
CL2016001098A1 (es) Uso de cisteamina y sus derivados para el tratamiento de enfermedades mitocondriales
EP3423881A4 (en) SYSTEM AND METHOD FOR IMAGING WITH DIFFUSION TO REDUCE SOURCE SELF-FLUORESCENCE AND IMPROVE UNIFORMITY
EP3325095A4 (en) SYSTEM AND METHOD FOR THE APPLICATION OF LIGHT THERAPY TO CURVED AND LARGE SURFACES
PH12016502284A1 (en) Cough medicine containing ambroxol hydrochloride
AR103636A1 (es) Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol
BR112015019792A2 (pt) composição para tratamento de hemorróidas e método de preparação
UA115417U (xx) Спосіб профілактики та лікування гіпоксичних змін при карбоперитонеумі

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20230705